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843-3 Late Quantitative Angiographic Results Following 
Treatment With a Polymer-Based Paclitaxel-Eluting 
Stent Compared With a Bare Metal Stent in Patients 
With De Novo Coronary Disease: The TAXUS-IV 
Angiographic Results
Jeffrey J. Popma, Stephen G. Ellis, David Cox, James Hermiller, Jr., Charles 
O'Shaughnessy, James Tift Mann, Mary E. Russell, Gregg Stone, The TAXUS IV 
Investigators, Cleveland Clinic Foundation, Cleveland, OH, Brigham and Women’s 
Hospital, Boston, MA
Background: A reduction in restenosis has been shown with paclitaxel-eluting stents in
patients with focal stenoses in native coronary arteries, but the benefit of these stents
has not been shown in more complex lesion subsets.
Methods: The TAXUS-IV study randomized 1,326 patients with complex coronary steno-
sis to single vessel treatment with the paclitaxel-eluting or bare metal Express™ stent. Of
these, 732 patients were assigned to 9 month angiographic follow-up and late repeat
angiography was performed in 559 (76.4%) of these patients. Quantitative angiographic
analysis (CMS, Medis) was performed at baseline, after the stent procedure and at late
angiographic follow-up. Analysis of the lumen changes within the stent (IS), its 5-mm
proximal and distal edges, and within the analysis segment (AS; in-stent plus 5 mm prox-
imal and distal) was performed.
Results: In patients assigned to angiographic restudy, diabetes was present in 25.8% of
patients, the reference vessel diameter was 2.8 mm, and the average lesion length was
14.4 mm. At late angiographic follow-up, there were significant reductions in all parame-
ters of late lumen re-narrowing with the use of the paclitaxel-eluting stent: 
Conclusions: We conclude that restenosis within the stent, within its 5-mm proximal and
distal edges, and within the analysis segment is significantly reduced with the use of the
paclitaxel-eluting stent.
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843-4 Reduction in Late Loss and Restenosis in Patients With 
Small Vessels Treated With the Slow Rate-Release, 
Polymer-Based Paclitaxel-Eluting Stent: Results From 
TAXUS-IV
Gregg W. Stone, Stephen G. Ellis, Charles O'Shaughnessy, James Tift Mann, Mark 
Turco, Albert Raizner, Louis Cannon, Michael Kutcher, Paul Gurbel, S. Chiu Wong, Mary 
E. Russell, Jeffrey J. Popma, The TAXUS IV Investigators, Cardiovascular Research 
Foundation, New York, NY, Brigham and Women's Hospital, Boston, MA
Background. The relative efficacy of the polymer based paclitaxel slow release eluting
TAXUS stent in small vessels with de novo lesions is unknown.
Methods. In the TAXUS-IV trial, 1,314 patients with de novo lesions ranging from 2.5 –
3.75 mm in diameter and 10-28 mm in length were randomized to treatment with the slow
rate-release, polymer-based paclitaxel-eluting TAXUS stent (n=662) vs. an identical
appearing uncoated EXPRESS stent (n=552).
Results. Of 1381 implanted stents, 424 (31%) were 3.5 mm in diameter, 669 (48%) were
3.0 mm diameter, and 288 (21%) were 2.5 mm in diameter. For the entire study popula-
tion, the TAXUS stent reduced the 9-month TLR and RR from 11.3% with BMS to 3.0%,
and from 26.6% to 7.9% respectively (both P<0.0001). As seen in the table, both TLR
and RRs progressively rose with decreasing stent size among patients receiving BMS. In
contrast, TLR and RRs were independent of stent size with the TAXUS stent. Among
BMS pts, absolute LL was independent of stent size, whereas with TAXUS, LL was signif-
icantly less in smaller stents. 
Conclusions. The paclitaxel-eluting TAXUS stent markedly reduces restenosis, indepen-
dent of vessel size, with reduced late loss and the greatest relative efficacy seen in the
smallest vessels.
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843-5 Drug-Eluting Stents for the Treatment of Bifurcated 
Coronary Lesions: A Randomized Comparison of 
Simple Versus Complex-Strategy Approach
Manuel Pan, Alfonso Medina, José Suárez de Lezo, Antonio Delgado, Miguel Romero, 
José Segura, Enrique Hernández, Djordje Pavlovic, Juan Herrador, Isabel Ureña, 
Federico Segura, Reina Sofía Hospital, Córdoba, Spain, Dr. Negrín Hospital, Las Palmas 
de Gran Canaria, Spain
Background: Rapamycin-eluting stents (RES) have shown to reduce restenosis in many
types of lesions. However, to date, the full reconstruction with RES of the entire bifurca-
tion has not been proven to improve the results of a simple strategy. Methods: To com-
pare both strategies we carried out a randomized study in 91 patients with true coronary
bifurcation lesions. All patients received a RES at the main vessel, covering the side
branch (SD). Patients from group A (n=47) were assigned to balloon dilation of the
involved SD (simple strategy); 44 patients (group B) were randomized to receive a sec-
ond stent at the SD origin (complex strategy). There were no differences between groups
regarding baseline clinical and angiographic data. One patient from group A crossed-
over to complex strategy due to a poor immediate result, whereas it was impossible to
implant a stent at the ostium of the SD in 4 patients from group B, so the intervention was
limited to balloon dilation. Results: The table summarizes the immediate and follow-up
results on an intention to treat basis. Six-month angiographic reevaluation was obtained
in 67 patients. Restenosis of the main vessel was observed in one patient from group A
(3%) and in 2 from group B (6%). Restenosis of the SD appeared in 2 patients from
group A (6%) and in 4 from group B (13%). Conclusions: Both strategies are effective,
without any differences in terms of clinical outcome. Elective SD stenting seems to pro-
vide no advantages over the simpler stent jail followed by SD balloon dilation. . 
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843-6 Three-Year Follow-Up of the RAVEL Study: A 
Randomized Study With the Sirolimus-Eluting Bx 
VELOCITY™ Stent in the Treatment of Patients With De 
Novo Native Coronary Artery Lesions
Marie-Claude Morice, Patrick Serruys, Costantino Costantini, Egon Wuelfert, William 
Wijns, Jean Fajadet, Antonio Colombo, Giulio Guagliumi, Ferenc Molnar, Ernesto Ban 
Hayashi, J. Eduardo Sousa, Marco Perin, The RAVEL Trial Investigators, Institut 
Cardiovasculaire Paris Sud, Massy, France
Background: Sirolimus, a macrocyclic antibiotic and immunosuppressant, causes late
G1 cell cycle arrest. A pilot study using Sirolimus-eluting stents to treat coronary artery
lesions demonstrated almost no neointimal hyperplasia at 12 months. Results from this
study were used to design RAVEL, a multicenter, double blind, two-arm, randomized
study assessing safety and effectiveness of the Sirolimus-Eluting BX VELOCITY™ stent
versus the uncoated Bx VELOCITY™ stent (18 mm).
Methods: The primary endpoint was angiographic late loss at 6 months. The secondary
endpoints were major adverse cardiac events, target vessel revascularization (TVR), tar-
get lesion revascularization (TLR) and restenosis rate. Inclusion criteria: stable or unsta-
ble angina, single treatment-de novo lesions < 18mm long, 2.5-3.5 mm diameter.
Clopidogrel or Ticlodipine was continued for up to 8 weeks following a loading dose.
Results: From August 2000-December 2000, 238 patients were enrolled at 19 sites in
Quantative Angiographic Analysis
Variable (Number of Lesions) EES (N=22) MS (N=43) P-value
Reference Diameter, mm 2.91±0.33 2.97±0.54 0.6
Final MLD, mm 2.88±0.29 2.87±0.42 0.9
Acute Gain, mm 1.83±0.52 1.83±0.42 1.0
FU Stent MLD, mm 2.74±0.28 2.02±0.74 <0.0001
FU Prox Stent Edge MLD, mm 2.65±0.66 2.66±0.64 1.0
FU Distal Stent Edge MLD, mm 2.43±0.47 2.36±0.53 0.6
Stent Late Loss, mm 0.12±0.28 0.85±0.58 <0.0001
Stent Restenosis, % 0.0% 19.4% 0.04
Segment Restenosis, % 4.8% 30.6% 0.04
Target Vessel Revascularization, % 0.0% 7.5% 0.5
MACE, % 4.8% 17.5% 0.2
Follow-up QCA Control Stent 
(N=357)
TAXUS Stent 
(N=375)
P value
MLD, IS/AS 1.75 / 1.68 2.26 / 2.03 < 0.001/<0.001
Edge, Proximal/Distal 2.51/2.25 2.58/2.34 0.20/0.04
% Stenosis, IS/AS 37.2 / 39.8 17.4 / 26.3 <0.001/ < 0.001
Late Loss, IS/AS 0.92 / 0.61 0.39 / 0.23 < 0.001 / < 0.001
Loss Index, IS/AS 0.56 / 0.48 0.23 / 0.38 < 0.001 / < 0.001
Binary Restenosis, IS/AS 24.4/ 26.6 5.5 / 7.9 < 0.001 / < 0.001
9 month rates by stent diameter Control TAXUS P value
TLR – 2.5 mm 18.0% 3.1% 0.0001
TLR – 3.0 mm 11.5% 3.7% 0.0002
TLR - 3.5 mm 7.3% 1.0% 0.002
RR – 2.5 mm 40.8% 8.8% 0.0002
RR – 3.0 mm 31.2% 9.1% <0.0001
RR – 3.5 mm 12.9% 5.5% 0.13
LL – 2.5 mm 0.65 mm 0.17 mm <0.0001
LL – 3.0 mm 0.61 mm 0.22 mm <0.0001
LL – 3.5 mm 0.60 mm 0.28 mm <0.0001
Immediate and follow-up results
Non-Q myocardial
infarction
Death Target lesion
revascularization
Total major cardiac
events at 6 months
Group A (n=47) 2 (4%) 0 1 (2%) 3 (6%)
Group B (n=44) 0 1(2%) 2 (5%) 3 (7%)
